Here, we uncovered that, after binding to RAGE, AGEs upregulated Sp1 expression via activating MEK1/2/ERK pathway, while the treatment of MEK1/2 inhibitor, U0126, reduced the AGEs-induced Sp1 expression in gastric cancer cells by blocking the activation of ERK. The gene discussed is MAP2K1; the disease is gastric cancer.